Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Great Point Partners Llc
Form 13F · Q2 2026

Great Point Partners Llc

CIK 1281446Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$529M
Reported book value
42
Positions
12
Quarters on record
Top 50
Positions

Great Point Partners Llc — holdings

Top 37 positions of 42, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1VOR Vor Biopharma Inc1.7M−2.9%$31M5.9%
2ABIVAX SA Abivax Sa204,314—$27M5.1%
3VERA Vera Therapeutics Inc600,836+201.4%$26M4.9%
4ZURA Zura Bio Ltd4.2M+0.0%$25M4.7%
5ALMS Alumis Inc856,061+0.0%$24M4.6%
6SLGL Sol-Gel Technologies Ltd274,363+0.0%$20M3.8%
7DFTX Definium Therapeutics Inc425,000—$20M3.8%
8ANNX Annexon Inc3.5M+40.0%$20M3.8%
9ORKA Oruka Therapeutics Inc183,330+0.0%$17M3.3%
10MLTX Moonlake Immunotherapeutics855,813+71.2%$17M3.1%
11SGMT Sagimet Biosciences Inc2.0M—$16M3.0%
12CTNM Contineum Therapeutics Inc921,481+15.2%$15M2.9%
13IMMX Immix Biopharma Inc1.3M+265.0%$13M2.5%
14CLYM Climb Bio Inc1.0M−25.0%$13M2.5%
15AMLX Amylyx Pharmaceuticals Inc700,000−60.0%$13M2.4%
16NKTR Nektar Therapeutics175,000−44.7%$12M2.3%
17NGNE Neurogene Inc352,180−29.6%$11M2.1%
18LBRX Lb Pharmaceuticals Inc317,221+5.7%$10M1.9%
19IRD Opus Genetics Inc2.0M+507.4%$8M1.5%
20EPRX Eupraxia Pharmaceuticals Inc1.2M+0.0%$8M1.5%
21DRUG Bright Minds Biosciences Inc109,603−50.2%$8M1.5%
22INFLARX NV Inflarx Nv3.0M—$7M1.3%
23RLMD Relmada Therapeutics Inc842,106+0.0%$6M1.1%
24JATT Jatt Ii Acquisition Corp500,000—$6M1.1%
25CGEM Cullinan Therapeutics Inc300,000+0.0%$5M1.0%
26ALT Altimmune Inc1.7M—$5M1.0%
27AMAN Amanat Acquisition Corp500,000—$5M1.0%
28RZLT Rezolute Inc951,809+0.0%$5M0.9%
29SLN Silence Therapeutics Plc450,000−55.9%$5M0.9%
30PALI Palisade Bio Inc2.3M−32.9%$5M0.9%
31EVMN Evommune Inc325,000+0.0%$4M0.8%
32SCYX Scynexis Inc944,292—$4M0.7%
33ELVN Enliven Therapeutics Inc70,000—$4M0.7%
34HUMA Humacyte Inc3.8M+0.0%$3M0.6%
35RNTX Rein Therapeutics Inc2.6M—$3M0.5%
36DBVT Dbv Technologies S A156,906—$3M0.5%
37PMN Promis Neurosciences Inc86,150−76.8%$1M0.2%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.